-
EP1357184
European procedure
Extract from the Register of European Patents
EP About this file: EP1357184
| EP1357184 - Novel cis-element decoys useful as anti-tumor therapeutics [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 05.09.2014 Database last updated on 27.07.2024 | Most recent event Tooltip | 05.09.2014 | No opposition filed within time limit | published on 08.10.2014 [2014/41] | Applicant(s) | For all designated states Nanjing Keygen Biotech. Co., Ltd. Floor 19, No. 486 Zhongshan East Road Nanjing (210002) P.R. China / CH | [2013/44] |
| Former [2003/44] | For all designated states Nanjing Keygen Biotech. Co., Ltd. Floor 19, No. 486 Zhongshan East Road Nanjing, (210002) P.R. China / CH | Inventor(s) | 01 /
Ye, Qing Nanjing Keygen Biotech. Co. Ltd Floor 19 486 Zhongshan, East Rd. Nanjing (210002) / CH | 02 /
Wang, Xuegen Nanjing Keygen Biotech. Co. Ltd Floor 19 486 Zhongshan, East Rd. Nanjing (210002) / CH | 03 /
Cheng, Wuling Nanjing Keygen Biotech. Co. Ltd Floor 19 486 Zhongshan, East Rd. Nanjing (210002) / CH | 04 /
Feng, Ying Nanjing Keygen Biotech. Co. Ltd Floor 19 486 Zhongshan, East Rd. Nanjing (210002) / CH | [2013/44] |
| Former [2003/44] | 01 /
Ye, Qing Nanjing Keygen Biotech. Co. Ltd, Floor 19 486 Zhongshan, East Rd. Nanjing (210002) / CH | ||
| 02 /
Wang, Xuegen Nanjing Keygen Biotech. Co. Ltd, Floor 19 486 Zhongshan, East Rd. Nanjing (210002) / CH | |||
| 03 /
Cheng, Wuling Nanjing Keygen Biotech. Co. Ltd, Floor 19 486 Zhongshan, East Rd. Nanjing (210002) / CH | |||
| 04 /
Feng, Ying Nanjing Keygen Biotech. Co. Ltd, Floor 19 486 Zhongshan, East Rd. Nanjing (210002) / CH | Representative(s) | TBK Bavariaring 4-6 80336 München / DE | [2013/44] |
| Former [2005/34] | TBK-Patent Bavariaring 4-6 80336 München / DE | ||
| Former [2003/44] | Leson, Thomas Johannes Alois, Dipl.-Ing. Patentanwälte Tiedtke-Bühling-Kinne & Partner, Bavariaring 4 80336 München / DE | Application number, filing date | 03007054.4 | 27.03.2003 | [2003/44] | Priority number, date | CH2112818 | 28.03.2002 Original published format: CH 2112818 | [2003/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP1357184 | Date: | 29.10.2003 | Language: | EN | [2003/44] | Type: | A3 Search report | No.: | EP1357184 | Date: | 23.06.2004 | [2004/26] | Type: | B1 Patent specification | No.: | EP1357184 | Date: | 30.10.2013 | Language: | EN | [2013/44] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 07.05.2004 | Classification | IPC: | C12N15/11, C07H21/00, A61K31/00 | [2003/44] | CPC: |
C12N15/113 (EP);
A61P35/00 (EP);
C12N15/1135 (EP);
A61K38/00 (EP);
C12N2310/13 (EP);
C12N2310/315 (EP)
| Designated contracting states | DE, FR, GB [2005/11] |
| Former [2003/44] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR | Title | German: | Neue cis-Element-Fallen zur Verwendung als Anti-Tumor-Therapeutika | [2003/44] | English: | Novel cis-element decoys useful as anti-tumor therapeutics | [2003/44] | French: | Nouveaux leurres d'elements cis utiles comme agents thérapeutiques antitumoraux | [2013/25] |
| Former [2003/44] | Nouveau leurre d'éléments cis utile comme agents thérapeutiques antitumorals | Examination procedure | 27.03.2003 | Examination requested [2003/44] | 16.02.2007 | Despatch of a communication from the examining division (Time limit: M04) | 25.06.2007 | Reply to a communication from the examining division | 22.08.2008 | Despatch of a communication from the examining division (Time limit: M04) | 29.12.2008 | Reply to a communication from the examining division | 11.08.2010 | Despatch of a communication from the examining division (Time limit: M04) | 09.12.2010 | Reply to a communication from the examining division | 08.02.2013 | Despatch of a communication from the examining division (Time limit: M02) | 05.04.2013 | Reply to a communication from the examining division | 03.06.2013 | Communication of intention to grant the patent | 17.09.2013 | Fee for grant paid | 17.09.2013 | Fee for publishing/printing paid | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 16.02.2007 | Opposition(s) | 31.07.2014 | No opposition filed within time limit [2014/41] | Fees paid | Renewal fee | 30.03.2005 | Renewal fee patent year 03 | 30.03.2006 | Renewal fee patent year 04 | 29.03.2007 | Renewal fee patent year 05 | 31.03.2008 | Renewal fee patent year 06 | 01.04.2009 | Renewal fee patent year 07 | 31.03.2010 | Renewal fee patent year 08 | 30.03.2011 | Renewal fee patent year 09 | 30.03.2012 | Renewal fee patent year 10 | 27.03.2013 | Renewal fee patent year 11 | Penalty fee | Additional fee for renewal fee | 31.03.2009 | 07 M06 Fee paid on 01.04.2009 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]EP0572287 (GENSET SA [FR]) [X] 1,4,5,7,11* the whole document *; | [X]WO9511687 (DZAU VICTOR J [US]) [X] 1-13,17-25 * the whole document *; | [X]US5683985 (CHU BARBARA CHEN FEI [US], et al) [X] 1-11,13,17-25 * the whole document *; | [X]US5780262 (BRENT ROGER [US], et al) [X] 1-11,16-25 * the whole document *; | [X]US5844096 (HINRICHS STEVEN H [US], et al) [X] 1-12,14,17-25 * the whole document *; | [X]WO9926634 (US HEALTH [US], et al) [X] 1-12,17-25 * abstract *; | [X] - LEE YOUL NAM ET AL, "CRE-transcription factor decoy oligonucleotide inhibition of MCF-7 breast cancer cells: Cross-talk with p53 signaling pathway", BIOCHEMISTRY, (20000425), vol. 39, no. 16, pages 4863 - 4868, XP002264482 [X] 1-12,17-25 * the whole document * DOI: http://dx.doi.org/10.1021/bi992272o | [X] - ALPER OZGE ET AL, "Apoptosis, growth arrest and suppression of invasiveness by CRE-decoy oligonucleotide in ovarian cancer cells: Protein kinase A downregulation and cytoplasmic export of CRE-binding proteins", MOLECULAR AND CELLULAR BIOCHEMISTRY, (200102), vol. 218, no. 1-2, pages 55 - 63, XP009022870 [X] 1-12,17-25 * the whole document * DOI: http://dx.doi.org/10.1023/A:1007205205131 | [X] - KUME MASAZUMI ET AL, "Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries", CIRCULATION, (20020312), vol. 105, no. 10, pages 1226 - 1232, XP002273848 [X] 1-11,13,17-25 * the whole document * DOI: http://dx.doi.org/10.1161/hc1002.104903 | [X] - SWANSON HOLLIE I ET AL, "Specificity of DNA binding of the c-Myc/Max and ARNT/ARNT dimers at the CACGTG recognition site", NUCLEIC ACIDS RESEARCH, (19990801), vol. 27, no. 15, pages 3205 - 3212, XP002273849 [X] 1-11,16-25 * the whole document * DOI: http://dx.doi.org/10.1093/nar/27.15.3205 | by applicant | WO9511687 | - DAM ET AL., ONCOGENE, vol. 20, pages 2453 - 2464 |